Prostate Cancer – Current Treatment – Current Treatment: Physician Insights – Prostate Cancer (US)

Hormonal therapy remains the foundation of drug treatment for prostate cancer across all patient populations, with ADT serving as the universal backbone. ARPIs—enzalutamide, apalutamide, and darolutamide—drive treatment in nmCRPC and mHSPC and remain widely used in mCRPC, although earlier-line intensification has shifted some use upstream. Chemotherapy continues to play a key role in advanced disease, while radioligand therapy is reshaping treatment options through the expanding use of Pluvicto in PSMA-positive mCRPC. PARP inhibitors, including olaparib, talazoparib, and niraparib, offer important biomarker-selected options for patients with HRR-mutated mCRPC and contribute to growing segmentation within the market. With multiple agents competing across lines of therapy and clinical factors strongly influencing selection, understanding real-world physician prescribing is essential for navigating today’s prostate cancer landscape.

Questions Answered

• What are the current drug-treatment rates and patient shares of key therapies across key prostate cancer populations?
• What considerations influence physicians’ choice among enzalutamide, darolutamide, and apalutamide for mHSPC?
• Which clinical factors most strongly drive physicians’ prescribing of PARP inhibitors for mCRPC HRR-mutated patients, and what obstacles—clinical, operational, or access-related—limit broader utilization?
• What benefits, requirements, and barriers do physicians report when considering Pluvicto for pre- and post-taxane mCRPC, and how do these factors shape its current positioning in practice?

Product Description

Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

• Understand the treatment landscape for a disease and how physicians make prescribing decisions.
• Evaluate the drivers and obstacles that influence treatment selection.
• Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.

Primary research: Survey of 100 medical oncologists in the United States fielded in December 2025.

Key drugs covered: Abiraterone, Enzalutamide, Apalutamide, Darolutamide, Docetaxel, Cabazitaxel, Olaparib, Niraparib, Talazoparib, 177Lu-PSMA-617.